AcquisitionsApr 7, 2026, 05:26 PM
Supernus Pharmaceuticals Acquires NV-5138/SPN-820 Compound Assets for Up to $350M in Milestone Payments
AI Summary
Supernus Pharmaceuticals, Inc. (SUPN) has entered into an Asset Purchase Agreement with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC to acquire all rights to the compound known as NV-5138 or SPN-820. The acquisition consideration includes an obligation for Supernus to complete one Phase 2b Study and make contingent milestone payments totaling up to $350 million based on development, regulatory, and commercial achievements. This strategic move expands Supernus's pipeline, building upon a prior Development and Option Agreement from April 21, 2020, and a Binding Memorandum of Understanding from May 5, 2025. The milestone-based payment structure aligns incentives and manages financial risk for the company.
Key Highlights
- Supernus Pharmaceuticals, Inc. acquired all rights, title, and interest in assets related to the compound NV-5138 or SPN-820 from Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC.
- The purchase price includes an obligation for Supernus to effect and complete one (1) Phase 2b Study.
- Supernus will make several milestone payments of up to $350 million, contingent upon the achievement of specified development, regulatory, and commercial milestones.
- The agreement was entered into on April 1, 2026, as contemplated by a Development and Option Agreement dated April 21, 2020, and a Binding Memorandum of Understanding dated May 5, 2025.
- Supernus has agreed to use commercially reasonable efforts to achieve the specified milestones for the compound.